White House fights Plan B subpoena

Share this article:
As the Bush White House vigorously resisted a Center for Reproductive Rights subpoena demanding internal documents that might show its involvement in the FDA's review of the emergency contraceptive Plan B, the center released a court deposition in which a key FDA official said it was involved.

FDA deputy director of new drugs Sandra Kweder said in the deposition that the agency's first “non-approvable” decision on Plan B in 2003 was “really rooted in” concerns from the White House and its supporters about two issues: availability to adolescents and, in Kweder's words, that “the public is not ready to have this kind of contraceptive so widely available over the counter, and that it's going to take time for the public to adjust to this idea.”

Kweder's deposition was taken by lawyers suing the FDA in New York federal court for age-unrestricted over-the-counter status for Plan B.

Earlier, the White House formally asserted separation of powers concerns among other arguments in objecting to the center's subpoena. In a letter to the center, Justice Department senior trial counsel John R. Tyler said a Supreme Court ruling that the White House is “unlike any other civil litigant” and that plaintiffs like CRR must “demonstrate a heightened and particularized need for discovery.”

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...